Figure 6
From: NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells
NT157 and gefitinib have potentiating antineoplastic effects on lung cancer cells. (a) The heatmap indicates the cell viability of H1299 and H460 cells treated with graded concentrations of NT157 (0.4, 0.8, 1.6, 3.2, and 6.4 μM) and gefitinib (3.2, 6.4, 12.5, 25, and 50 μM) alone or in combination with each other for 48 h, as indicated. Increased cell viability is indicated by green color, while reduced cell viability is indicated by red color. (b) Dose–response cytotoxicity for NT157 in combination with gefitinib (25 or 50 μM) for H1299 and H460 cells. Values are expressed as the percentage of viable cells for each condition relative to untreated controls. Results are shown as the mean of at least three independent experiments. (c) Western blot analysis of p-AXLTyr702, AXL, p-SAPK/JNKThr183/185, SAPK/JNK in H1299 and H460 cells treated with vehicle, NT157 (12.5 μM) and/or gefitinib (25 μM) for 24 h. Membranes were reprobed with the antibody for the detection of the respective total protein or α-tubulin, and developed with the SuperSignal™ West Dura Extended Duration Substrate system using a G:BOX Chemi XX6 gel doc imaging system.
